Depo-Provera Lawsuit | Meningioma Brain Tumor Claims & 2025 Litigation Update
Depo-Provera Lawsuit | Meningioma Brain Tumor Claims & 2025 Litigation Update
By Credible Law — A San Diego–based legal referral network connecting clients to proven product-liability counsel. This article is for informational purposes only and is not legal advice.
Why you’re here (and what you’ll get)
If you or a loved one used Depo-Provera (depot medroxyprogesterone acetate, DMPA) and later learned of a meningioma (a tumor that forms in the brain’s protective membranes), you’re likely asking:
- Is there credible science behind a link?
- Who’s being sued and why?
- What makes a strong Depo-Provera lawsuit?
- Is there a class action or an MDL?
- What compensation might be available and how long could it take?
This guide answers those questions in one place, with plain-English explanations, citations to leading medical and regulatory sources, and practical steps to protect your legal rights. We also track the 2025 litigation landscape so you can make timely decisions.
At a glance: Multiple peer-reviewed studies and international regulators have flagged an increased relative risk of meningioma with prolonged or high-dose medroxyprogesterone acetate (including injectables like Depo-Provera). U.S. lawsuits are consolidated in federal court, and judges are moving bellwethers forward.
Contents
- What is Depo-Provera and what’s alleged?
- The science: what reputable studies and regulators say
- 2024–2025 litigation posture (MDL, bellwethers, defenses)
- Do you qualify to file? (medical & legal criteria)
- Evidence checklist & “first 30 days” action plan
- Damages, settlement factors & timelines
- FAQs (schema-ready)
- How Credible Law helps (risk-free case review)
- Sources & further reading
What is Depo-Provera and what’s alleged?
Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate (MPA). Plaintiffs allege that:
- Long-term or high-dose exposure to MPA elevates the risk of intracranial meningioma for some users.
- Manufacturers failed to adequately warn patients and prescribers in a timely, prominent way about brain-tumor risks; that safer labeling or risk minimization should have been implemented earlier; and that U.S. marketing understated neurologic risks.
- Secondary claims focus on bone mineral density loss/osteoporosis (a known risk with DMPA that carries a U.S. boxed warning), as well as blood clots, certain cancers, and potential infertility.
These allegations form the basis for product-liability suits (e.g., failure to warn, design/labeling defects) and, where applicable, wrongful-death claims.
The science: what reputable studies and regulators say
Peer-reviewed epidemiology
- BMJ (2024): A national case–control study from France reported that prolonged use of medroxyprogesterone acetate (and a few other progestogens) was associated with increased meningioma risk, with injection-specific signals highlighted as new and important.
- JAMA Neurology (2025): A large U.S. cohort analysis found depot medroxyprogesterone acetate use was associated with a relative risk ~2.4 for meningioma versus matched controls (RR 2.43; 95% CI 1.77–3.33).
- Expert Opinion on Drug Safety (2025): A nested case-control study (Frey et al.) linked MPA use to a substantially increased meningioma risk, reinforcing concerns about long-term DMPA exposure.
- Systematic reviews/overviews (2024–2025): Summaries in peer-reviewed venues note the growing—though still evolving—evidence base connecting DMPA with intracranial meningioma, while advising clinical caution and informed consent.
Important nuance: Researchers emphasize relative risk can rise with long duration/high dose, but absolute risk remains small, because meningiomas are uncommon. That’s also the position of several regulators.
Global regulators & safety communications
- EMA/PRAC (EU) reviewed evidence and acknowledged an increased risk with high-dose MPA (including injectables), especially with prolonged use; risk-reduction measures were recommended.
- MHRA (UK) issued a DHPC (Direct Healthcare Professional Communication): highlight meningioma risk, advise contraindications for patients with a history of meningioma, and stress benefit-risk discussions.
- Medsafe (New Zealand) recognized meningioma as a newly identified, very rare adverse effect of MPA and advised discontinuation if meningioma occurs.
- Other agencies (e.g., Pakistan DRAP) have echoed PRAC’s stance on monitoring and risk minimization.
FDA labeling & manufacturer position (U.S.)
- The U.S. FDA label for Depo-Provera contains a long-standing boxed warning on bone density loss, but Pfizer contends the agency declined in late 2023 to add a tumor-risk warning based on the evidence then available; in Aug 2025 court filings, Pfizer argues federal preemption (i.e., it couldn’t unilaterally change the U.S. label). Plaintiffs disagree, alleging earlier knowledge and inadequate warnings.
Why this matters legally: If a court finds the FDA wouldn’t have allowed the warning plaintiffs say was required, some failure-to-warn claims could be preempted. Plaintiffs will counter with newer data, international actions, and internal-knowledge arguments.
2024–2025 litigation posture (MDL, bellwethers, defenses)
- In February 2025, federal Depo-Provera brain-tumor cases were centralized in the Northern District of Florida as In re: Depo-Provera Products Liability Litigation (an MDL). Centralization streamlines discovery, expert challenges, and bellwether trials that can shape global resolution strategies. King Law
- The MDL docket now includes hundreds of filed cases, with bellwether selections underway to test general causation and warnings theories. Plaintiffs focus on meningioma (primary injury), with secondary claims like bone density injuries. Defense themes include preemption and causation challenges. King Law
- Legal media and plaintiff updates forecast case-management conferences, Daubert (expert admissibility) briefing, and trial-ready waves into late 2025–2026, though timetables can shift. (For an overview from neutral and plaintiff-side trackers, see litigation explainers.) Lawsuit Information Center+1
Do you qualify to file? (medical & legal criteria)
While every claim is fact-specific, attorneys commonly evaluate:
- Exposure: Documented Depo-Provera injections (or depo subQ provera 104) for ≥ 1–2 years before diagnosis strengthens some causation theories (duration matters in several studies).
- Injury: A physician-diagnosed meningioma (benign or atypical), confirmed by MRI/CT and pathology if resected. Associated neurologic sequelae (e.g., vision changes, headaches, seizures, cognitive effects) should be captured.
- Timing: Symptom onset and diagnosis dates relative to injection history are crucial (look-back windows can vary by expert model).
- Jurisdiction: Statutes of limitations/repose differ by state; MDL filing preserves federal claims while state deadlines still matter.
- Labeling & notice: Counsel will analyze the evolution of warnings, prescriber knowledge, and what reasonable warnings should have said at the time of your use.
Eligibility examples (not exhaustive):
- “meningioma diagnosis after depo provera shot,” “long term depo provera use brain tumor risk,” “depo provera lawsuit compensation brain tumor,” “depo provera brain tumor lawsuit eligibility,” “depo provera lawsuit update brain tumor 2025.”
- If you used a generic medroxyprogesterone acetate, you may still qualify; counsel will vet labeling and supplier-specific issues.
Evidence checklist & “first 30 days” action plan
Medical proof
- Pharmacy printouts / EHR showing Depo-Provera (or depo subQ provera 104) NDCs, dates, dose.
- Imaging (MRI/CT), radiology reads, neurosurgery notes, pathology (WHO grade).
- Symptom logs: headaches, vision problems, seizures, chronic pain, cognitive or mood changes (helps tie damages like lost wages or pain and suffering).
Administrative proof
- Insurance EOBs, work-leave records (FMLA/SDI), disability filings.
- Out-of-pocket costs and travel receipts.
Action plan (30 days)
- Request complete medical records (OB-GYN, primary care, neuro-oncology).
- Create a treatment timeline (first injection → last injection → first symptoms → diagnosis → surgery/radiation).
- Stop gap: Speak with your clinician about risks/benefits of continuing DMPA and alternatives (we do not give medical advice).
- Consult qualified counsel quickly to preserve claims and avoid deadline traps.
- Avoid social-media speculation; it can be discoverable (yes, even “depo Provera lawsuit reddit” threads can be misread without context).
Damages, settlement factors & timelines
Potential damages (case-dependent):
- Economic: medical bills (past/future), rehab, home modifications, lost wages/earning capacity, caregiving.
- Non-economic: pain and suffering, emotional distress, loss of consortium.
- Wrongful death: funeral costs, survivors’ losses.
Settlement drivers
- Duration/dose of DMPA use (exposure strength).
- Tumor burden (size, multiplicity), surgery or radiation, permanent deficits (e.g., vision loss), and life-care plans.
- Causation quality (expert support aligned with evolving literature and regulatory positions).
- Defenses (e.g., preemption based on FDA labeling posture; alternative causes).
Timelines
- MDL cases typically run 18–36+ months to bellwether resolutions or global talks. Individual outcomes vary; some settle earlier, others go to trial. (Trackers regularly post Depo-Provera lawsuit settlements 2024 roundups; remember those figures are often projections or single-case anecdotes, not guarantees.) Lawsuit Information Center
Strategically weaving key search terms (for user intent & SEO)
We naturally cover and contextualize the phrases users actually type—never “stuffed,” always reader-first:
- Core queries people ask: Depo Provera lawsuit, Depo-Provera lawsuit, depo Provera class action lawsuit, depo Provera shot lawsuit, Depo-Provera brain tumor lawsuit, lawsuit for depo Provera, lawsuit depo Provera, depo Provera lawsuits, Depo-Provera lawsuit side effects, Depo-Provera lawsuit settlements, depo Provera lawsuit reddit, Depo-Provera lawsuit settlements 2024, Depo-Provera lawsuit 2024, depo Provera lawsuit 2024, Depo-Provera shot lawsuit.
- Long-tails aligned to real decisions: depo provera failure to warn lawsuit, depo provera bone density loss lawsuit, depo provera black box warning lawsuit, depo provera long term bone loss compensation, depo provera blood clots lawsuit eligibility, depo provera pulmonary embolism legal claim, depo provera severe depression mood swings lawsuit, long term infertility after depo provera lawsuit, statute of limitations depo provera lawsuit state, depo provera lawsuit attorneys near me, depo provera lawsuit for women under 35.
Pro-tip for readers: If you’re comparing resources, you may also see explainer content at health/law sites (and even recovery resources like The Recover, which often educates patients about co-occurring medical/legal concerns). Use those for context—not as a substitute for direct legal counsel.
FAQs (schema-ready)
Each answer is concise for on-page readability; your counsel can expand based on your records.
General Information & Basis of the Lawsuit
1) What is the Depo-Provera lawsuit primarily about?
Allegations center on failure to warn about an increased meningioma risk associated with prolonged or high-dose medroxyprogesterone acetate (DMPA) injections, plus secondary injuries (e.g., bone density loss/osteoporosis). Plaintiffs argue earlier, stronger U.S. warnings were warranted.
2) What is a meningioma, and what is its alleged connection to Depo-Provera?
A meningioma is a usually benign brain tumor arising from the meninges. Multiple studies report elevated relative risk with long-term DMPA exposure. Absolute risk remains low, but for affected patients, the harm can be significant (surgery, neurologic deficits).
3) Does Depo-Provera also cause other serious health issues cited in lawsuits (e.g., bone density loss, osteoporosis)?
Yes—bone mineral density loss with DMPA is established and boxed-warned in the U.S.; some suits also allege clots, certain cancers, and infertility, depending on the case. (Talk to your doctor before changing medications.) Lawsuit Information Center
4) Who is being sued in the Depo-Provera litigation?
Primarily Pfizer (and related entities). Some complaints also name distributors or generics where applicable.
5) What is the legal basis for the Depo-Provera lawsuits (e.g., failure to warn, product liability)?
Typical theories include failure to warn, negligence, design/labeling defects, breach of warranties, and in some cases fraud/misrepresentation.
6) Are the Depo-Provera lawsuits a “class action” or a “mass tort/MDL”?
They’re proceeding as a federal MDL (consolidated for pretrial), not a single nationwide class for personal injury damages. Individual injuries differ too much for one damages class. King Law
Eligibility and Filing a Claim
7) Am I eligible to file a Depo-Provera lawsuit? What are the key criteria?
Documented DMPA injections, a meningioma diagnosis, and temporal linkage (exposure before diagnosis). Duration, dose, and medical records matter.
8) How long must I have used Depo-Provera to qualify for a claim?
Studies focus on prolonged use; many firms look for ≥ 1–2 years of injections, but counsel will review all timelines.
9) Do I qualify if I used a generic version (medroxyprogesterone acetate)?
Possibly. Liability may extend to generic suppliers depending on jurisdictional and labeling issues; counsel will analyze your pharmacy records.
10) Do I qualify if my meningioma was “benign” (Grade 1)?
Yes. Benign meningiomas can still cause serious neurologic harm and require surgery/radiation.
11) Is there a deadline (Statute of Limitations) for filing?
Yes. Deadlines vary by state. Don’t delay; an attorney can calculate your SOL and any applicable repose periods.
12) What documentation do I need to start a claim?
Medication history (injection dates/NDCs), imaging/pathology, surgeon/oncology notes, work/insurance records (damages).
13) What are common symptoms that should prompt me to speak with a doctor and an attorney?
Headaches, vision changes, seizures, cognitive/mood shifts, focal neurologic deficits—see your clinician promptly; then explore your legal options.
Legal Process and Compensation
14) How much does it cost to hire an attorney?
Most firms offer contingency fees—you pay no fees unless there’s a recovery. Confirm terms in writing.
15) How long will the case take?
MDLs often run 18–36+ months through bellwethers. Some resolve earlier; others proceed to trial. King Law
16) What is the potential value or estimated settlement amount?
Values depend on exposure, tumor severity, permanency, lost earnings, and venue. Public “Depo-Provera lawsuit settlements 2024” posts are directional only—not guarantees. Lawsuit Information Center
17) What types of compensation can be recovered?
Medical costs, lost wages/earning capacity, pain and suffering, loss of consortium, and, in qualifying cases, wrongful-death damages.
18) If I have pre-existing conditions or risk factors, can I still file?
Yes. Pre-existing conditions don’t bar claims; they factor into causation and apportionment analyses.
Safety and Medical Guidance
19) Should I stop using Depo-Provera if I’m concerned?
Only your healthcare professional can advise on treatment changes. Discuss risks, alternatives, and your medical history. (This article isn’t medical advice.)
20) Has the FDA or manufacturer added meningioma warnings in the U.S.?
Court filings indicate Pfizer argued the FDA declined a requested tumor-risk label change in late 2023; the company relies on preemption defenses. Plaintiffs counter with new data and international actions. Labeling remains a moving target; check the current PI and talk to your doctor.
How Credible Law helps (risk-free case review)
- Rapid records triage: We help you gather medical/pharmacy proofs quickly.
- National network: We connect you with vetted product-liability counsel experienced in pharma MDLs.
- No-pressure intake: Understand your options, deadlines, and likely next steps—before you commit.
Start a confidential case screen in minutes.
Sources & further reading
- BMJ (2024)—French case–control study on progestogens and meningioma (includes DMPA injectable signal).
- JAMA Neurology (2025)—DMPA and meningioma risk (RR ≈ 2.43).
- EMA/PRAC Highlights (2024)—Increased risk with high-dose MPA; safety measures.
- MHRA DHPC (UK, 2024)—Risk communication and minimized use guidance.
- Medsafe (NZ, 2025)—Meningioma recognized as very rare MPA side effect.
- MDL status & defense posture (2025)—Litigation centralized; Pfizer’s preemption filing reported. King Law
- Additional overviews & explainers—Neutral and plaintiff-side trackers for context. Lawsuit Information Center
Legal disclaimer: This content is educational. It does not create an attorney-client relationship, nor does it replace individualized legal or medical advice. Always consult a licensed attorney about your specific facts and a licensed clinician about medical care.
